Precision for Medicine Expands Its Global Footprint for Oncology Development Services

BETHESDA, Md., July 6, 2017 /PRNewswire/ -- Precision for Medicine today reported important progress in its global expansion plan. Precision for Medicine, with its oncology research team Precision Oncology, is rapidly expanding its global footprint to better serve clients developing oncology treatments. Investment in executive leadership and operational teams are underway across Europe, providing integrated, full-service clinical trial execution services throughout the continent.

With headquarters in Paris, France, and an office in Edinburgh, Scotland, Precision currently has staff in 5 countries in the EU and will expand to 8 countries by early 2018. The company is proud to report that the leadership team is in place, led by Clare Sarvary Fourrier, Senior Vice President of Clinical Operations Europe, and Andrea Cotton-Berry, Head of Business Development and Strategic Operations EU and APAC. Prior to joining Precision, Clare and Andrea held senior leadership positions at global CROs where they were responsible for leading early oncology drug development. Clare and Andrea lead a seasoned EU management group in the oncology drug development environment. The consolidation of this position in Europe is aimed at offering the quality services that are a company hallmark to a wider base of European clients operating in the oncology drug development sector.

"Precision is a company with vision and purpose and the commitment to investing in the services our clients need, where they need them," Sarvary Fourrier said. "I am thrilled to be involved in this innovative approach to providing comprehensive services to our clients that are purposefully designed to meet the evolving environment of oncology treatment research."

As part of the global expansion, Precision has grown its Oncology Site Network (OSN) in Western Europe to include more than 20 cancer treatment centers, with a goal of 40 network sites throughout Europe in 2018. This offering enhances the Precision solution for accelerated oncology development through faster study start-up, dialogue with oncology clinical experts, and stronger site engagement. 

"We are very excited to continue to enlarge our European footprint to support our life sciences clients. The additions of our offices in Paris and Edinburgh will help us rapidly expand our team of oncology and biomarker experts, critical to supporting our clients' scientific and operational needs," said Precision for Medicine President Chad Clark.

Precision is the first precision medicine research company focused on biomarker-driven therapeutic development. The company combines the highest standards in clinical trial management with the most advanced biomarker capabilities to provide clients with a streamlined development solution. Its unique model allows developers to make better-informed decisions, thereby accelerating the development pathway.

The strategic growth of labs, trial execution, and Precision's site network is expected to continue throughout the remainder of 2017 and into the first quarter of 2018, including the addition of other European offices.

About Precision for Medicine and Precision Oncology
Precision Oncology is part of Precision for Medicine and offers oncology developers an accelerated pathway for novel oncology drug development. With expertise in early phase oncology trial operations combined with integrated biomarker services, Precision Oncology has changed the way sponsors outsource their oncology trials by providing strategic consultation and full-service trial operations, based on the power of precision medicine.

SOURCE Precision for Medicine